drugset / Trial / NCT02745704
The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg
Phase 4
Unknown
200 enrolled
Third Affiliated Hospital, Sun Yat-Sen University
First Affiliated Hospital of Kunming Medical University · collabFirst People's Hospital of Foshan · collabFirst People's Hospital, Shunde China · collabHuazhong University of Science and Technology · collabHuizhou Municipal Central Hospital · collabNanchang University · collabPeking University · collabShenzhen Third People's Hospital · collabTang-Du Hospital · collabYuebei People's Hospital · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
As HBsAg clearance is uncommon in chronic hepatitis B (CHB) patients on nucleoside analogues (NAs) therapy. The purpose of this study is to optimize HBsAg clearance in CHB Patients with sequential treatment of pegylated interferon alpha and NAs.
Timeline
- Start
- 2016-04
- Primary completion
- 2019-04
- Completion
- 2019-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peginterferon alfa-2a | Protein / enzyme biologic | 180 ug | — |
| Subject | Peginterferon alfa-2b | Protein / enzyme biologic | 80 ug | — |